Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.70 USD
Change Today -1.40 / -8.70%
Volume 19.7K
CORI On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 12:47 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

corium international inc (CORI) Snapshot

Open
$15.40
Previous Close
$16.10
Day High
$15.84
Day Low
$14.63
52 Week High
08/3/15 - $16.29
52 Week Low
11/17/14 - $4.30
Market Cap
265.8M
Average Volume 10 Days
61.1K
EPS TTM
$-1.45
Shares Outstanding
18.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORIUM INTERNATIONAL INC (CORI)

Related News

No related news articles were found.

corium international inc (CORI) Related Businessweek News

No Related Businessweek News Found

corium international inc (CORI) Details

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips, which are a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, which delivers ethinyl estradiol and levonorgestrel hormones has completed a Phase III clinical trial; MicroCor hPTH(1-34), a transdermal system that has completed a Phase I clinical trial for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed a Phase I clinical trial for the treatment of benign prostatic hyperplasia. In addition, it is developing a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness; a generic transdermal product for the treatment of a urologic condition, as well as Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Par Pharmaceutical, Inc.; Agile Therapeutics, Inc.; and others. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

244 Employees
Last Reported Date: 12/15/14
Founded in 1995

corium international inc (CORI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $582.3K
Chief Financial Officer
Total Annual Compensation: $467.3K
Chief Technology Officer and Vice President o...
Total Annual Compensation: $392.2K
Compensation as of Fiscal Year 2014.

corium international inc (CORI) Key Developments

Corium International Mulls Acquisitions

Corium International, Inc. (NasdaqGM:CORI) is seeking acquisitions. Corium International, Inc. has filed a follow-on equity offering. Corium intends to use the net proceeds from the offering for general corporate purposes, which may include funding research and development, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to its own and capital expenditures.

Corium International, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015; Provides Revenue Guidance for the Fourth Quarter and Full Year of 2015

Corium International, Inc. announced unaudited earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company’s total revenues were $10,598,000 compared to $10,183,000 a year ago. Loss from operations was $3,994,000 compared to $3,397,000 a year ago. Loss before income taxes was $5,914,000 compared to $4,981,000 a year ago. Net loss and comprehensive loss was $5,914,000 or $0.33 per diluted share compared to $4,981,000 or $0.28 per diluted share a year ago. The increase in total revenues primarily resulted from growth in contract research and development revenues, as well as recognition of a new consumer product launch milestone, partially offset by the continued declines in product revenues from Fentanyl TDS (marketed by Par Pharmaceutical) and Clonidine TDS (marketed by Teva Pharmaceuticals). Product revenues for the quarter was $6.3 million compared with $7.9 million in the third quarter of fiscal 2014. This decrease in product revenue was primarily due to the continued decline in revenues from Clonidine product, as it has experienced increased competition, including a third competitor that launched in May of 2014. For the nine months, the company’s total revenues were $31,655,000 compared to $31,368,000 a year ago. Loss from operations was $14,334,000 compared to $5,253,000 a year ago. Loss before income taxes was $19,813,000 compared to $3,545,000 a year ago. Net loss and comprehensive loss was $19,815,000 or $1.10 per diluted share compared to net loss and comprehensive loss of $3,545,000 or $0.48 per diluted share a year ago. The increase in total revenues primarily reflects an increase in contract research and development revenues from co-development and partner funded programs, partially offset by expected declines in product revenues from Fentanyl TDS and Clonidine TDS. Corium would have recognized a non-GAAP net loss of $10.9 million for the nine months ended June 30, 2014. Product revenues were $20.5 million compared with $23.2 million in the same period of fiscal 2014. This decrease in product revenue is primarily due to the anticipated declines in revenues from Clonidine and Fentanyl products. The company expect the fourth fiscal quarter to continue or accelerate that decline in product revenues. The company announced current outlook on full year total revenue is now between $39 million and $40 million. The annual measurement period for minimum revenue covenant of senior debt ended on June 30, and the company exceeded that minimum with revenues of $42.7 million. The next measurement date for this covenant will not be until June 30, 2016, at which time, the $40 million in revenue threshold will again apply for the proceeding 12 months.

Corium International, Inc., Q3 2015 Earnings Call, Jul 29, 2015

Corium International, Inc., Q3 2015 Earnings Call, Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORI:US $14.70 USD -1.40

CORI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $152.57 USD +0.14
FUJIFILM Holdings Corp ¥4,941 JPY -31.50
Mylan NV $54.37 USD -0.83
Zogenix Inc $19.60 USD 0.00
Zosano Pharma Corp $7.71 USD -0.225
View Industry Companies
 

Industry Analysis

CORI

Industry Average

Valuation CORI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORIUM INTERNATIONAL INC, please visit www.coriumgroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.